MedTrace Logo

Effect of Palonosetron on Remifentanil for Preventing Emergence Cough in Female

NCT04563260 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2021-05-11

No results posted yet for this study

Summary

The primary purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in female patients who receive the palonosetron or not.

Conditions

  • Gallbladder Diseases

Interventions

DRUG

Normal saline injection

Normal saline 2 mL, intravenous injection

DRUG

Palonosetron Injection [Aloxi]

Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection

Sponsors & Collaborators

  • Ajou University School of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2021-03-19
Completion
2021-03-19

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04563260 on ClinicalTrials.gov